CD437

Research use only, not for human use.

CD437 is a specifc Retinoic Acid Receptor γ (RARγ) agonist.

CD437 is a synthetic retinoid that is an RARγ-selective agonist. It displays RARγ-dependent and -independent effects on differentiation and apoptosis. CD437 induces apoptosis and acts synergistically with TRAIL receptor-2 agonist in malignant melanoma. CD437 inhibits DNA replication in cells and recombinant POLA1 activity in vitro.(In Vitro):CD437 is a selective RARγ agonist. Growth inhibition by CD437 in these lung cancer cell lines is apparent after 2 days of treatment with 10 μM CD437. Dose-response experiments demonstrate that CD437 reduces the numbers of H460, SK-MES-1, A549, and H292 cells with 50% inhibitory values of approximately 0.5, 0.4, 3, and 0.85 μM, respectively. Treatment for 72 h with CD437 causes a strong dose-dependent growth inhibition in all melanoma cell lines. At a concentration of 5 μM CD437, only about 5 to 25% of the cells remain viable after 3 d. The concentrations of CD437 required for 50% growth inhibition (IC50) range from 10 μM for MeWo to 0.1 μM for SK-Mel-23 showing the highest sensitivity.(In Vivo):Tumors in CD437-treated mice stop growing, an effect that becomes already statistically significant (P<0.01) at day 13, 3 d after first administration of CD437, and is maintained for more than 3 wk after discontinuation of treatment. Further histologic analysis demonstrates marked c-fos mRNA levels at the tumor-stroma edge in CD437-treated tumors.

——

——

CD437 | CD 437 | CD-437 | Ro-472077

Microbiology/Virology

HBV

RARγ

Cancer

——

125316-60-1

398.49

C27H26O3

>98% (HPLC)

DMSO : 150 mg/mL. 376.42 mM;

O=C(C1=CC=C2C=C(C3=CC=C(O)C(C4(C5)CC6CC5CC(C6)C4)=C3)C=CC2=C1)O

6-[3-(1-adamantyl)-4-hydroxyphenyl]naphthalene-2-carboxylic acid

(-20℃)

With Ice Pack

≥ 2 years